Latest Breaking News On - Neurocrine biosciences - Page 13 : vimarsana.com

Jennison Associates LLC Grows Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Jennison Associates LLC Grows Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United-states
Ingrid-delaet
Neurocrine-biosciences
Cantor-fitzgerald
Red-spruce-capital
Neurocrine-biosciences-inc
Barclays
Securities-exchange-commission
Exchange-commission
Metis-global-partners
Jennison-associates
Goldman-sachs-group

Jennison Associates LLC Increases Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Jennison Associates LLC Increases Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

United-states
Neurocrine-biosciences
Eric-benevich
Kevin-charles-gorman
Nasdaq
Jennison-associates
Jpmorgan-chase-co
Metis-global-partners
Sunbelt-securities-inc
Lindbrook-capital
Needham-company
Neurocrine-biosciences-inc

Wells Fargo becomes bullish on this biotech company

Wells Fargo believes the company's hyperplasia and depression treatments could each become over $1 billion opportunities.

Japan
Japanese
Neurocrine-biosciences
Mohit-bansal
Wells-fargo
Analyst-mohit-bansal
Breaking-news-investing
Wall-street
Business
Markets
Stock-markets
Wells-fargo-amp-co

Mid-Stage Win for Novel Depression Agent; 'Floordrobe' Disorder; CIA Mind Control

News and commentary from the psychiatry world

New-york
United-states
South-korea
South-korean
Neurocrine-biosciences
Bryant-shuey
University-of-pittsburgh-school-medicine
New-york-post
Health-forum
Patient-health-questionnaire
Lancet-psychiatry
Pittsburgh-school

Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS ...

LEXINGTON, Mass., April 22, 2024 (GLOBE NEWSWIRE) Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that it will present a broad set

Michael-grannan
Damien-maura
Varshini-venkatesan
Todd-carter
Adam-bero
Shiron-lee
Hechen-bao
Roberto-facendola
Brett-hoffman
Matteo-placidi
Tyler-moyer
Trista-morrison

Biotech Stock Neurocrine Launches Higher On A Depression Treatment Win

Biotech Stock Neurocrine Launches Higher On A Depression Treatment Win
investors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investors.com Daily Mail and Mail on Sunday newspapers.

Neurocrine-biosciences
Laura-chico
Takeda-pharmaceutical

The No. 1 Biotech Stock Just Launched Higher

Top-notch biotech stock Neurocrine Biosciences (NBIX) launched higher Tuesday after the company's Takeda Pharmaceutical (TAK)-partnered depression treatment…

Neurocrine-biosciences
Takeda-pharmaceutical
News
Ggregator
Reaking-news
Uration
Edia

Neurocrine Biosciences (NBIX) Reports Positive Phase 2 Data for NBI-1065845

Neurocrine Biosciences (NBIX) Reports Positive Phase 2 Data for NBI-1065845
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Neurocrine-biosciences
Eiryw-roberts
Nasdaq
Neurocrine-biosciences-inc
Depression-rating-scale
Chief-medical-officer

Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder

Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Eiryw-roberts
Neurocrine-biosciences
Drug-administration
Nasdaq
Twitter
Linkedin
Exchange-commission
Neurocrine-biosciences-inc
Facebook
Prnewswire-neurocrine-biosciences-inc
Study-met-primary-endpoint
Statistically-significant-reduction

Phase 2 SAVITRI Supports Use of NBI-1065845 in Major Depressive Disorder with Inadequate Response to Antidepressants

NBI-1065845 shows promise in alleviating symptoms of major depressive disorder in patients with inadequate response to current antidepressant treatments, according to phase 2 SAVITRI study data.

Holgersfotografie-pixabay
Neurocrine-biosciences
Eiryw-roberts
Takeda-pharmaceuticals
Neurocrine-biosciences-inc
Depression-rating-scale
Neurocrine-biosciences-reports
Adults-with-major-depressive-disorder